Critical Questions in Choosing EGFR-Targeted Therapies for NSCLC - Episode 7

Treatment Sequencing in Disease Progression in EGFRm NSCLC

April 21, 2025

Christine M. Lovly, MD, PhD, Balazs Halmos, MD, MS

Panelists discuss how, after the MARIPOSA regimen, second-line therapy selection depends on resistance mechanisms, prior toxicity, and patient factors. MARIPOSA-2 vs PALOMA-3 choices are influenced by efficacy in resistant mutations and safety profiles, per European Society for Medical Oncology 2023/2024 and American Society of Clinical Oncology 2024 data.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Brief Overview of the Treatment Landscape of First-Line EGFRm NSCLC

EP. 2: FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach

EP. 3: Clinical Factors to Consider When Choosing a Treatment Strategy

EP. 4: Treatment Strategies to Manage AEs in EGFRm NSCLC

EP. 5: The Multidisciplinary Team’s Role in EGFRm NSCLC Management

EP. 6: Role of Rebiopsy at Disease Progression in EGFRm NSCLC

Now Viewing

EP. 7: Treatment Sequencing in Disease Progression in EGFRm NSCLC

EP. 8: Looking Into the Future and at Unmet Needs in EGFRm NSCLC

Video content above is prompted by the following:

Looking at treatment sequencing, how do you approach second-line therapy after:
- MARIPOSA regimen?
- What factors influence your choice between MARIPOSA-2 and PALOMA-3?
- MARIPOSA-2: Passaro A, et al. ESMO Congress 2023. Abs LBA15, Popat S, et al. ESMO 2024. Abs LBA54.
- PALOMA-3: Leighl NB, et al. ASCO 2024. Abs LBA8505.